Brandy Eling, NP
Nurse Practitioner · Denver, CONPI 1700487741
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,702 of the $3,256 with a category attached, or 83.0%. It is spread thinly across 35 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,730, more than ten times the $43 reported in 2021. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $29.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$641
- Bristol Myers Squibb$305
- AbbVie$257
- AstraZeneca$175
- Legend Biotech USA Inc.$173
- Pfizer$152
- plus $2K from 29 others
What the payments were for
- Consulting fees$1755%
- Food & beverage$2,70283%
- Education$37912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,256 in reported general payments places this provider in the 90th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 27 | $1,121 |
| Omeprazole | 11 | $177 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $161 |
| Acyclovir | 18 | $70 |
| Trazodone Hcl | 13 | $25 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Denver
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
- Lolanda McBrideDenver$20K
- Cori FratelliDenver$15K
- Leslie HindsDenver$9K
- Rebecca AndrieDenver$8K
- Nahid Kuseh Kalani YazdDenver$8K
- Amber Whitton-SmithDenver$7K
- Jacqueline CarboneDenver$7K
- Stephanie WyttenbachDenver$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.